For research use only. Not for use in humans.

Anti-mouse MHC Class II (I-A/I-E)-InVivo

Synonyms: I-A/I-E, H-2 class II Clone No.:M5/114

Anti-mouse MHC Class II (I-A/I-E)-InVivo reacts with mouse MHC Class II haplotypes I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek. The antibody does not react with I-Af, I-Ak, or I-As haplotypes. The M5/114 antibody is reported to inhibit I-A-restricted T cell responses.

Anti-mouse MHC Class II (I-A/I-E)-InVivo

Quality Control

Batch: A216904 Purity: 99% Protein concentration: 11.28 mg/ml Endotoxin Level: <1EU/mg
99

Product Details

Clone M5/114
Isotype Rat IgG2b
Application Anti-mouse MHC Class II (I-A/I-E)-InVivo
Source CHO
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS, pH 7.0. Contains no stabilizers or preservatives
Murine Pathogen Screening Panel all targets tested yielded Negative Results: Theiler’s Murine Encephalomyelitis Virus, Ectromelia (Mousepox) Virus, Hantavirus, Polyomavirus, Sendai Virus, Mycoplasma pulmonis, Pneumonia Virus of Mice, K Virus, Mouse Parvovirus, Mouse Hepatitis Virus, Mouse Norovirus, Mouse Minute Virus, Mouse Cytomegalovirus, Mouse Adenovirus, Lactate Dehydrogenase-Elevating Virus, Reovirus Panel, Lymphocytic Choriomeningitis Virus, Mouse Rotavirus.
Storage
(From the date of receipt)
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07072585 NOT_YET_RECRUITING Drug: Bortezomib|Drug: Calaspargase Pegol|Drug: Cyclophospha Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma; T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma Children's Oncology Group 2026-08-28 PHASE2; PHASE3
NCT05463133 RECRUITING Drug: Sirolimus|Drug: Cyclophosphamide|Drug: Alemtuzumab|Dru Chronic Granulomatous Disease National Institute of Allergy and Infectious Diseases (NIAID) 2022-07-08 PHASE1; PHASE2
NCT07697456 RECRUITING Drug: Risankizumab|Drug: Trosunilimab|Drug: ABBV-701 Crohn's Disease; Ulcerative Colitis AbbVie 2026-07-31 PHASE2
NCT07570966 WITHDRAWN Drug: ERW316|Drug: Fulvestrant|Drug: Letrozole Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Metastatic Castration-resistant Prostate Cancer (mCRPC) Novartis Pharmaceuticals 2026-06-30 PHASE1; PHASE2
NCT07288359 RECRUITING Drug: GVV858|Drug: Fulvestrant|Drug: Letrozole Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Metastatic Castration-resistant Prostate Cancer Novartis Pharmaceuticals 2025-12-29 PHASE1; PHASE2
NCT02813135 RECRUITING Drug: Ribociclib|Drug: Topotecan|Drug: Temozolomide|Drug: Ev Pediatric Cancer Gustave Roussy, Cancer Campus, Grand Paris 2016-08-03 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-07-30)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.